Concepedia

Paul Statkevich

PS

Statistics

Publications

77

Citations

6K

H-Index

38

Active since

1993

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

Bristol-Myers Squibb (United States)

The University of Texas MD Anderson Cancer Center

AGCO (United Kingdom)

The University of Texas at San Antonio Health Science Center

Paul Statkevich is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in pharmacology, medicine, and pharmacy.

ORCID

Publications per year

1993–2024

77

Publications

77

Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant Melanoma

Mark R. Middleton, Jean‐Jacques Grob, Neil K. Aaronson et al. · Journal of Clinical Oncology · 2000 · 1.3K citations

, , +12

Clinical trial of a farnesyltransferase inhibitor in children with Hutchinson–Gilford progeria syndrome

Leslie B. Gordon, Monica E. Kleinman, David T. Miller et al. · Proceedings of the National Academy of Sciences · 2012 · 370 citations · Full text

, , +13

Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules

Anthony W. Tolcher, Stanton L. Gerson, Christiane Geyer et al. · British Journal of Cancer · 2003 · 369 citations · Full text

, , +16

Absorption, metabolism, and excretion of 14C-temozolomide following oral administration to patients with advanced cancer.

Sharyn D. Baker, Mark Wirth, Paul Statkevich et al. · PubMed · 1999 · 225 citations

, , +16

Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies

M. Brada, Ian Judson, Philip Beale et al. · British Journal of Cancer · 1999 · 208 citations · Full text

, , +17

1–5 of 77